|
2011/09/15
Hui-Fang Lv1, 2, Yu-Qing Xu2, Rong-Rong Song3, Huan-Ren4, Hong-Wei Xu4, Wen-Xiu Wang2, Cheng-Bin Zhao5, Jing Qu5,
FengLian5, Chan Li6, Hong Zhang6, Ai-Shun Jin4, Hiroyuki Abe7, Ben-Ning Zhang4, Yun-Long Qi∗5
1 Department of Oncology, Henan Cancer Hospital; Zhengzhou University
2 Department of Oncology, the Second Affiliated Hospital of Harbin Medical University
3 Department of Neurology, the Fourth Affiliated Hospital of Harbin Medical University
4 Department of Immunology, Harbin Medical University
5 Department of Orthopedics, the Fourth Affiliated Hospital of Harbin Medical University
6 Department of Neuropathology, Medical Research Institute, Tokyo Medical and Dental University
7 Kudan Clinic, the Institute of Medical Oncology
Abstract
To investigate the efficacy of autologous Natural killer (ANK) cell therapy in the treatment of advanced prostate cancer,
we selected nine patients with advanced prostate cancer and metastatic lesions for this study.
Approximately 1×109 ANK cells were injected into each patient every 2 weeks or every month.
A combination of ANK cell injections were performed over 20 injections. During the course of therapy, we adopted face
scale as measurement of quality of life (QOL) and the CD4+ to CD8+ T cell ratio served as a marker of immunological status.
The administration of ANK cells resulted in prolonged survival (≥3 year) of all nine patients in our study.
The QOL of each study participant remained satisfactory or improved, over the course of treatment and their immune status
also improved following ANK cell therapy.
The results indicate that ANK cell therapy is a safe and partially effective treatment for patients with advanced prostate cancer.
• 국제저널 통합의료학회(지) vol. 4 No.1: 80-85,
|
